NCT03805841终止2 期
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 41
- 试验地点
- 9
- 主要终点
- ORR
研究概览
简要总结
Open-label, Phase 2, single treatment arm, 3 cohorts
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically and/or cytologically confirmed primary diagnosis of NSCLC, Stage IV, Stage IIIB or IIIC not amenable to definitive curative intent therapy, or recurrent disease after prior diagnosis of Stage I-III disease. Cohort C locally advanced or metastatic solid tumor.
- •Progression of disease on or after a platinum-based chemotherapy regimen (Cohorts A and B) or after standard of care (Cohort C)
- •EGFR exon 20 insertion mutation (Cohort A) or HER2 activating mutation (Cohort B) or NRG1 or ERBB family gene fusions (Cohort C)
- •Measurable disease according to RECIST v.1.1
- •ECOG performance status of 0 or 1
- •Serum creatinine ≤ 1.5 x ULN (or calculated creatinine clearance ≥ 60 mL/min using Cockcroft Gault equation)
- •Total bilirubin: ≤ 1.5 x ULN or ≤ 3 x ULN in the presence of liver metastases
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN, in the presence of liver metastases
- •Absolute neutrophil count (ANC) ≥ 1,500 cells/μL
- •Hemoglobin ≥ 9 g/dL or 5.6 mmol/L
- •Platelet count ≥ 100,000/μL
- •No evidence of second or third degree atrioventricular block
- •No clinically significant arrhythmia (i.e.; pauses of > 4 seconds, VT of any duration, SVT > 4 beats/minute)
- •QRS interval ≤ 110 ms
- •QTcF interval of < 450 ms
- •PR interval ≤ 200 ms
- •Adequate pretreatment tumor sample (125 µm of FFPE block or at least 8 prepared slides)
排除标准
- •Another known activating oncogene driver mutation
- •(Cohorts A and B Only) Previously received anti EGFR or anti HER2 tyrosine kinase inhibitors
- •(Cohorts A and B Only) Previously received anti EGFR or anti HER2 monoclonal antibodies or EGFR or HER2 antibody drug conjugates
- •Investigational therapy administered within the 28 days or 5 half lives
- •Chemotherapy or radiation within 14 days prior to Cycle 1 Day 1
- •Immunotherapy within 21 days
- •Clinically active or symptomatic interstitial lung disease (ILD) or interstitial pneumonitis, or a history of clinically significant ILD or radiation pneumonitis
- •Untreated and/or symptomatic CNS malignancies (primary or metastatic);
- •Receiving medication that prolongs QT interval, with a risk of causing Torsade de Pointes (TdP)
- •Personal or familial history of Long QT Syndrome
- •NYHA class III or IV or LVEF < 55%
- •Myocardial infarction, severe or unstable angina within 6 months
- •History of TdP, ventricular arrhythmia
- •Significant thrombotic or embolic events within 3 months
- •Uncontrolled or severe cardiovascular disease
- •Concurrent malignancy expected to require treatment within 2 years or interfere with study outcomes
- •History of severe allergic reactions or hypersensitivity to compounds of similar chemical or biologic composition as tarloxotinib
- •Known HIV infection or active Hepatitis B or C
研究组 & 干预措施
Active
Experimental
tarloxotinib bromide
干预措施: tarloxotinib bromide (Drug)
结局指标
主要结局
ORR
时间窗: Through study completion, an average of 10 months.
The primary objective of this study is to evaluate the objective response rate (ORR) of tarloxotinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for tumors assessed by CT or MRI: Complete Response (CR) - Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to ≤10 mm. Partial Response (PR) - ≥30% decrease in the sum of the longest diameter of the target lesions compared with baseline. The overall response rate in each cohort will be estimated as the number of subjects with a confirmed objective response (CR or PR) divided by the number of enrolled subjects in each respective cohort.
次要结局
未报告次要终点
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)Non Small Cell Lung Cancer MetastaticNCT03353675Transgene44
招募中
1 期
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic CancerPancreatic CancerNCT05827796InxMed (Shanghai) Co., Ltd.70
Unknown
2 期
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 PositiveCervical CancerNCT03808857Genor Biopharma Co., Ltd.80
进行中（未招募）
2 期
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerPancreatic CancerNCT04390399ImmunityBio, Inc.328
进行中（未招募）
2 期
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)Warm Autoimmune Hemolytic Anemia (wAIHA)NCT05002777Sanofi22